戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 le null mice (-/Y) developed testes but were hypogonadal.
2 o 96 years]); 71 (17.5%) of the 405 men were hypogonadal.
3 .04 L) older than 54 years; 38 patients were hypogonadal-a prevalence similar to that reported in the
4                                     Nineteen hypogonadal and 20 eugonadal men with COPD (FEV(1) 1.14
5                       Mutant female mice are hypogonadal and demonstrate decreased levels of serum es
6 terans Short Form-36) were equivalent in the hypogonadal and eugonadal groups.
7 ysis showed a significant difference between hypogonadal and eugonadal men in time to diagnosed depre
8                                              Hypogonadal and eugonadal patients had equivalent limb m
9 g progressive inspiratory threshold loading, hypogonadal and eugonadal patients had similar respirato
10 by phrenic nerve stimulation, was similar in hypogonadal and eugonadal patients: 20.6 +/- 2.2 and 19.
11         Male Nhlh2-/- mice are microphallic, hypogonadal and infertile with alterations in circulatin
12                                Patients were hypogonadal, and one of them also had type 2 diabetes me
13 ACE and TD would be observed when women were hypogonadal, and that treatment with estradiol would att
14 1r KOs (lacking Kiss1r in just BAT) were not hypogonadal, as expected.
15  in an impaired healing model (mice rendered hypogonadal) associated with increased matrix deposition
16 roles of androgen and estrogen deficiency in hypogonadal bone loss are unclear.
17        Ascorbic acid may prevent FSH-induced hypogonadal bone loss by modulating the catabolic action
18 er, TNFalpha-deficient mice are resistant to hypogonadal bone loss despite having elevated FSH, sugge
19                              We propose that hypogonadal bone loss is caused, at least in part, by en
20             We show that FSH is required for hypogonadal bone loss.
21  We suggest that high circulating FSH causes hypogonadal bone loss.
22 lishes a role of gut microbiota in mediating hypogonadal bone loss.
23        Female Nhlh2-/- mice reared alone are hypogonadal, but when reared in the presence of males, t
24 n associated with this therapy may lead to a hypogonadal condition that can have detrimental effects
25 y relevant mood symptoms during this induced hypogonadal condition.
26 phasis on the critical interpretation of the hypogonadal conditions throughout the lifespan of the ma
27  that YKL-05-099 increases bone formation in hypogonadal female mice without increasing bone resorpti
28 or immunoreactivity (IR) in the brain of the hypogonadal (hpg) male mouse, genetically deficient in G
29 ophysectomized mice, gonadotrophin-deficient hypogonadal (hpg) mutant mice, and androgen receptor-def
30 n of GnRH, functions absent in patients with hypogonadal hypogonadism.
31   The prevalences that were based on FT (ie, hypogonadal &lt; 52 pg/dL) and BAT (ie, hypogonadal < 95 ng
32 FT (ie, hypogonadal < 52 pg/dL) and BAT (ie, hypogonadal &lt; 95 ng/dL) were 78% and 66%, respectively.
33                        We tested here, using hypogonadal luteinizing hormone/choriongonadotropin rece
34                                       In the hypogonadal man whose only complaint is decreased libido
35               These patients-if diagnosed as hypogonadal-may benefit from the short- and long-term ef
36 erm Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) Study, which evaluated the ef
37 tudies suggested that tumors that develop in hypogonadal men are more aggressive.
38   Testosterone replacement therapy may offer hypogonadal men benefit, but long-term studies on its ef
39  at any site did not significantly differ in hypogonadal men compared with eugonadal men (for example
40 in postmenopausal women, but its efficacy in hypogonadal men is not known.
41                                              Hypogonadal men showed an increased incidence of depress
42 of diagnosed depressive illness was 21.7% in hypogonadal men vs 7.1% in others (chi2(1)=6.0, P=.01).
43                    Eighty-three older, obese hypogonadal men with frailty were randomly assigned to l
44 nt therapy increases bone mineral density in hypogonadal men, including men with hypopituitarism.
45 he prevention and perhaps treatment of AD in hypogonadal men.
46  of both overall QoL and sexual function for hypogonadal men.
47 d effective strategy to prevent bone loss in hypogonadal men.
48 n, but whether these changes represent early hypogonadal metabolic dysfunction warrants further inves
49                                              Hypogonadal mice (whether by castration or by treatment
50 , the same cell populations are increased in hypogonadal mice or male castrates.
51                        Estrogen treatment of hypogonadal mice reduced precursors to normal.
52 wise, complexes isolated from the ovaries of hypogonadal mice, which lack circulating gonadotropins,
53 ly and not unexpectedly, probiotics reversed hypogonadal osteopenia in sex steroid-deficient mice by
54                                              Hypogonadal patients had decreased total QoL scores on F
55 (ie, TT < 300 ng/dL) was 48%, and mean TT in hypogonadal patients was 176 ng/dL.
56                The mean FT and BAT values in hypogonadal patients were 25 pg/dL and 45 ng/dL, respect
57 ith eugonadal patients, we hypothesized that hypogonadal patients with COPD have decreased respirator
58 store testosterone to the eugonadal range in hypogonadal patients with either unilateral or bilateral
59  likely contributes to the hypogonadotrophic hypogonadal phenotype in individuals with PWS.
60  lumbar punctures were performed during both hypogonadal (placebo) and testosterone-replaced conditio
61 ased sexual interest was observed during the hypogonadal state compared with both baseline and testos
62                       In addition, the early hypogonadal state is characterized by decreased total li
63 y and withdrawal from these high levels to a hypogonadal state were simulated by inducing hypogonadis
64 ) to the healthy male volunteers, creating a hypogonadal state, and then either replaced testosterone
65 ass (adjusted for weight) are related to the hypogonadal state.
66 ead to expression of the alpha subunit and a hypogonadal state.
67 f the male individual, with the exception of hypogonadal states resulting from congenital disorders o
68  scanning genes in its vicinity in unrelated hypogonadal subjects, we have identified WDR11 as a gene
69 e efficacy of testosterone in alleviation of hypogonadal symptoms (diminished libido, depressed mood,
70 osterone concentrations less than 300 ng/dL, hypogonadal symptoms, and cardiovascular disease (CVD) o
71 erone concentration results below 300 ng/dL, hypogonadal symptoms, and cardiovascular disease (CVD) o
72 e sufficient to cause depressive symptoms in hypogonadal women.
73 ssessed in six experiments performed on four hypogonadal women.